mutLBSgeneDB |
Gene summary for TYK2 |
![]() |
Basic gene Info. | Gene symbol | TYK2 |
Gene name | tyrosine kinase 2 | |
Synonyms | IMD35|JTK1 | |
Cytomap | UCSC genome browser: 19p13.2 | |
Type of gene | protein-coding | |
RefGenes | NM_003331.4, | |
Description | non-receptor tyrosine-protein kinase TYK2 | |
Modification date | 20141221 | |
dbXrefs | MIM : 176941 | |
HGNC : HGNC | ||
Ensembl : ENSG00000105397 | ||
HPRD : 01490 | ||
Vega : OTTHUMG00000166373 | ||
Protein | UniProt: P29597 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_TYK2 | |
BioGPS: 7297 | ||
Pathway | NCI Pathway Interaction Database: TYK2 | |
KEGG: TYK2 | ||
REACTOME: TYK2 | ||
Pathway Commons: TYK2 | ||
Context | iHOP: TYK2 | |
ligand binding site mutation search in PubMed: TYK2 | ||
UCL Cancer Institute: TYK2 | ||
Assigned class in mutLBSgeneDB | A: This gene has a literature evidence and it belongs to targetable_mutLBSgenes. | |
References showing study about ligand binding site mutation for TYK2. | 1. "Staerk J, Kallin A, Royer Y, Diaconu CC, Dusa A, Demoulin JB, Vainchenker W,Constantinescu SN. JAK2, the JAK2 V617F mutant and cytokine receptors. Pathol Biol (Paris). 2007 Mar;55(2):88-91. Epub 2006 Aug 14" 16904848 2. "Gakovic M, Ragimbeau J, Francois V, Constantinescu SN, Pellegrini S. The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor. J Biol Chem. 2008 Jul 4;283(27):18522-9. doi: 10.1074/jbc.M801427200. Epub 2008 May 2." 18456658 |
![]() |
GO ID | GO Term | PubMed ID |
Top |
Ligand binding site mutations for TYK2 |
![]() We represented ligand binding site mutations only. (You can see big image via clicking.) ![]() |
![]() |
![]() |
LBS | AAchange of nsSNV | Cancer type | # samples | N734 | H732R | COAD | 1 | R503 | R501W | GBM | 1 | C536 | G535D | HNSC | 1 | D1041 | D1041A | KIRC | 1 | R521 | S522F | SKCM | 1 | K930,A928 | V929M | UCEC | 1 | G906,F908 | H907N | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for TYK2 |
![]() Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
![]() ![]() |
![]() |
![]() Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | R521 | S522F | 0.2181314 | D1041 | D1041A | -0.92266415 | G906 | H907N | -0.86186515 | F908 | H907N | -0.86186515 | A928 | V929M | -0.81962878 | K930 | V929M | -0.81962878 | R503 | R501W | -0.80277644 | N734 | H732R | -0.4757276 | C536 | G535D | -0.21016693 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
![]() |
Top |
Differential gene expression and gene-gene network for TYK2 |
![]() |
![]() |
Top |
Top |
Phenotype information for TYK2 |
![]() |
Disease ID | Disease name | # PubMed | Association type |
umls:C0026769 | Multiple Sclerosis | 8 | Biomarker, GeneticVariation |
umls:C0033860 | Psoriasis | 4 | Biomarker, GeneticVariation |
umls:C0010346 | Crohn Disease | 3 | Biomarker, GeneticVariation |
umls:C0003873 | Arthritis, Rheumatoid | 3 | Biomarker, GeneticVariation |
umls:C1969086 | Tyrosine Kinase 2 Deficiency | 1 | Biomarker, GeneticVariation |
umls:C0236736 | Cocaine-Related Disorders | 1 | Biomarker |
umls:C0023892 | Liver Cirrhosis, Biliary | 1 | Biomarker |
umls:C1456784 | Paranoid Disorders | 1 | Biomarker |
![]() |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for TYK2 |
![]() Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
![]() |
![]() |
![]() |
![]() |
Drug status | DrugBank ID | Name | Type | Drug structure |
Experimental | DB04716 | 2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE | Small molecule | ![]() |
Experimental | DB08183 | 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile | Small molecule | ![]() |
![]() |
![]() |
![]() |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | 5U3 | 3-AZANYL-5-[(2~{S})-3-METHYLBUTAN-2-YL]-7-[1-METHYL-5- (2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]-1~{H}-PYRAZOLO[4, 3-C]PYRIDIN-4-ONE | 5f1z | A | A928 | 0X6 | 2,6-DICHLORO-4-CYANO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE | 4gii | A | A928 D1041 | 0XH | 2,6-DICHLORO-N-[2-({[(1R,2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4- YL]BENZAMIDE | 4gj2 | A | A928 D1041 | 0XP | 2,6-DICHLORO-4-CYANO-N-[2-({[(1R,2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4- YL]BENZAMIDE | 4gj3 | A | A928 D1041 | 0X5 | 2,6-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN- 4-YL}BENZAMIDE | 4gih | A | A928 D1041 | ADP | ADP | 4gvj | A | A928 K930 D1041 | 2YK | 6-[(2,5-DIMETHOXYPHENYL)SULFANYL]-3-(1-METHYL-1H- PYRAZOL-4-YL)[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE | 4py1 | A | A928 K930 D1041 | MG | MAGNESIUM(2+) | 4gvj | A | D1041 | MG | MAGNESIUM(2+) | 4gvj | A | D1041 | TZ1 | N-{5-[(7-CHLOROQUINOLIN-4-YL)SULFANYL]-1,3,4-THIADIAZOL-2-YL}THIOPHENE-2-CARBOXAMIDE | 3nyx | A | F908 A928 K930 D1041 | IZA | 2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE | 3lxp | A | G906 A928 | 0X2 | 2,6-DICHLORO-N-(2-OXO-2,5-DIHYDROPYRIDIN-4-YL)BENZAMIDE | 4gfo | A | G906 A928 | IZA | 2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE | 3nz0 | A | G906 A928 D1041 | 5U4 | 3-AZANYL-5-(2-METHYLPHENYL)-7-(1-METHYLPYRAZOL-3-YL)- 1~{H}-PYRAZOLO[4,3-C]PYRIDIN-4-ONE | 5f20 | A | G906 A928 D1041 | MI1 | CP-690,550 | 3lxn | A | G906 A928 K930 D1041 | 2TT | 2-CHLORO-N-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4- YL}BENZAMIDE | 4oli | A | G906 D1041 | AGS | ADENOSINE 5'-[GAMMA-THIO]TRIPHOSPHATE | 5c03 | A | N734 | AGS | ADENOSINE 5'-[GAMMA-THIO]TRIPHOSPHATE | 5c03 | B | N734 | III | Peptide ligand (ASN,LEU,LEU,LEU,SER,THR,SER,GLU,GLU,GLN,ILE,GLU,LYS,CYS,PHE,ILE,ILE,GLU,ASN) | 4po6 | A | R503 R521 C536 |
Top |
Conservation information for LBS of TYK2 |
![]() |
LBS | AA sequence | # species | Species |
![]() |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |